Business

Cephalgia, a startup spun out of the University of Chicago, will receive $250,000 from the university’s Innovation Fund for development of intranasal IGF-1 for the treatment of migraine, according to the fund. The company was… Read more . . .

Intranasal drug developer Impel NeuroPharma has received $21 million in the initial tranche of a Series C financing round, with another $15 million available on completion of development and business milestones, the company said. Investors… Read more . . .

Teva Israel and Syqe Medical have announced that Teva will distribute Syqe’s cannabis inhaler in Israel, with Syqe responsible for manufacturing the inhaler and cartridges. No financial terms were disclosed. The Syqe device delivers 100… Read more . . .

On November 14, 2016, Judge Sue Robinson of the US District Court for the District of Delaware issued a ruling upholding Merck’s US patent 6,127,353 but finding that Teva’s mometasone nasal spray ANDA does not… Read more . . .

Pharmaxis will collaborate with the Woolcock Institute of Medical Research to develop a tobramycin dry powder inhaler for the treatment of cystic fibrosis, the company has announced. A A$421,545 grant from the Australian National Health… Read more . . .

According to MannKind Corporation, it has reached an agreement with Sanofi regarding the return of rights to Afrezza inhaled insulin, in which “All issues arising out of the license and collaboration agreement, the supply agreement,… Read more . . .

Johnson & Johnson subsidiary Cilag GmbH International will pay a total of $330 million to AstraZeneca for rights to Rhinocort Aqua budesonide nasal spray outside of the US, AstraZeneca has announced. Cilag operates as part… Read more . . .

Mast Therapeutics has announced that it will stop its development program for vepoloxamer and will devote its resources to development of AIR001 sodium nitrite inhalation solution for patients with heart failure with preserved ejection fraction… Read more . . .

The US Patent and Trademark Office (USPTO) has awarded US Patent No. 9,446,134 (“Stabilizing alkylglycoside compositions and methods thereof”) to Aegis Therapeutics, the company said. The patent covers an intranasal formulation of octreotide, which is… Read more . . .